iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
MALVERN, Pa., Nov. 30, 2017 -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a partnership with Apple (NASDAQ:AAPL) to provide cardiac monitoring services in conjunction with the Apple Heart Study. The study, which launched today, is expected to discover undiagnosed irregular heart rhythms, such as atrial fibrillation, using the Apple Watch and the dedicated “Apple Heart Study” App.
Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “We are extremely excited to be participating in this potentially ground-breaking study. Too often, the first indication of a cardiac arrhythmia is the occurrence of a life-threatening event. The Apple initiative will potentially benefit countless individuals who are unaware that they may be at risk for serious health issues.”
About BioTelemetry
BioTelemetry, Inc. is the leading mobile and wireless medical technology company focused on delivery of health information to save and improve lives while reducing the cost of care. The Company provides cardiac monitoring, mobile blood glucose monitoring, centralized medical imaging, and original equipment manufacturing that serve both the Healthcare and Clinical Research industries. More information can be found at www.gobio.com.
Contact:
BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
[email protected]
